Giro

Selected form

Ornidazole

Method of action: Antiprotozoal

Treatment option: Abscess, Liver Abscess, Dysentery

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Giro

Quick Facts: Giro (Ornidazole)

Property	Description
Active ingredient	Ornidazole
Pharmacological class	Antiprotozoal agent, Anaerobicidal agent
Manufacturer	Panacea Biotec Ltd.
General purpose	Elimination of susceptible protozoa and anaerobic bacteria
Origin	Synthetic compound (nitroimidazole derivative)

What Type of Medicine is Giro and Its Chemical Origin?

Giro is a branded prescription-only (Rx) pharmaceutical product whose sole active ingredient is Ornidazole. This substance is a synthetic compound that belongs to the nitroimidazole derivative class of antimicrobial agents, which are characterized by a potent, targeted action.

Ornidazole is utilized as a monotherapy, meaning it is the only active substance responsible for the therapeutic effect. Pharmacological studies suggest Ornidazole is noted for having a longer elimination half-life compared to some older agents in its class, a factor that may be considered in determining the dosing regimen.

The Purpose of Giro: An Antiprotozoal and Anaerobicidal Agent

The general therapeutic purpose of Giro is defined by its role as a dual-action antiprotozoal and anaerobicidal agent. This means the medicine is clinically recognized for its ability to eliminate infections caused by two specific types of pathogens: parasitic organisms known as protozoa and susceptible anaerobic bacteria. This specialized classification ensures the drug is applied only when these specific types of oxygen-intolerant organisms are involved.

The medicine operates via a selective chemical activation. Ornidazole is inert until it enters a susceptible microbe, where it is metabolized to generate highly reactive molecules. These molecules then directly disrupt the pathogen's DNA structure, halting its ability to reproduce and survive.

Available Pharmaceutical Forms and Routes of Action

Giro and other Ornidazole preparations are manufactured in several pharmaceutical formulations to suit different clinical applications. The common dosage forms include the oral tablet, the solution for intravenous infusion (for systemic action throughout the body), and the vaginal suppository (for local action). This range of forms allows the medicine to be administered for either systemic or topical/local action, ensuring the active ingredient reaches the site of the susceptible pathogens effectively.

Regulatory References

What side effects are possible with Giro?

The official safety profile for Giro (Ornidazole) is established through structured regulatory documents that classify potential adverse reactions based on frequency and affected body system.

Adverse Reaction Scope

Adverse reactions are formally categorized across several physiological domains, with a particular emphasis on the Nervous System and the Gastrointestinal System. Gastrointestinal issues, such as nausea, vomiting, and an unpleasant metallic taste in the mouth, are among the more commonly reported effects.

Classification	Examples of Documented Effects
Uncommon	Diarrhea, loss of appetite, skin reactions, itching.
Very Rare	Seizures, poor coordination, peripheral neuropathy (tingling/numbness in extremities), and temporary loss of consciousness.
Not Known	Anaphylaxis, angioedema (severe swelling), jaundice, hepatitis, and severe psychiatric disorders (e.g., confusion).

Serious Adverse Reactions

The regulatory safety information highlights the potential for rare but serious adverse reactions, including severe neurological events (such as convulsive seizures and ataxia), severe hypersensitivity reactions (anaphylaxis), and hepatobiliary injury (jaundice or hepatitis). These events, while rare, are explicitly documented in official product labeling.

Population-Specific Safety Considerations

The official label contains specific safety statements regarding certain patient groups. Caution is advised for individuals with known pre-existing Central Nervous System diseases, such as epilepsy or multiple sclerosis. For patients with severe hepatic (liver) impairment, official documentation specifies that the dosing interval should be adjusted due to the drug's prolonged elimination half-life.

Safety-Related Restrictions

Ornidazole is contraindicated in individuals with known hypersensitivity to any nitroimidazole derivative. Additionally, regulatory documents state that the consumption of alcohol during therapy and for a period afterward may result in adverse consequences, such as flushing, nausea, and vomiting. Due to the potential for dizziness and other neurological effects, the ability to operate machinery may be impaired.

Connection to the overall safety profile

This structured safety information defines the officially recognized risk landscape of Giro by clearly separating expected adverse effects from rare, critical events. It establishes clear boundaries and limitations concerning pre-existing conditions and concurrent substance use, strictly based on government-approved prescribing information.

Overdose and Emergency Response

Suspected overdosage of Giro (Ornidazole) requires seeking immediate medical attention. The official regulatory profile for Ornidazole outlines specific clinical manifestations and associated emergency responses for overexposure.

Documented Overdose Manifestations

Documented signs of overexposure are linked to the central nervous system and the gastrointestinal tract. Clinical manifestations include somnolence (drowsiness) and headache. Patients may also experience severe gastrointestinal disturbances, such as pronounced nausea and vomiting. Regulatory documentation notes that these symptoms typically present with a greater severity than the undesirable effects seen during routine use.

Severe Outcomes and Emergency Response

A critical manifestation of overdosage is the development of cramps. Official guidance addresses this severe event by specifically recommending the administration of diazepam for its management. Furthermore, the drug’s safety profile notes that overexposure may lead to the aggravation of pre-existing severe diseases of the central and peripheral nervous system, reinforcing the necessity for prompt medical care.

Overdose management is characterized as entirely symptomatic and supportive, as regulatory labeling explicitly states that no specific antidote is known for Ornidazole.

Therapeutic Uses of Giro

Quick Facts

Therapeutic Domain: Management of bacterial and parasitic infections.
Key Uses: Addresses infections in the digestive system, including amoebiasis and giardiasis.
Additional Role: May be utilized to support infection prevention following surgical procedures.

Giro is indicated for the management of infections caused by certain types of bacteria and parasitic organisms. It is a prescription medication used to address a variety of bodily infections, often targeting those in the gastrointestinal tract, such as giardiasis and amoebiasis. Additionally, Giro may be part of a regimen to manage liver abscesses and specific types of genital or urinary tract infections.

The medication is also utilized to help prevent infections that may occur after certain surgical procedures. Using Giro as directed by a healthcare professional may support the resolution of infection-related symptoms, promoting an eventual return to health.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Giro (Ornidazole) — Official Regulatory Information

The eligibility profile for Giro is defined by governmental regulatory authorities, establishing strict rules on who may receive the medicine.

Eligibility Status	Applicable Populations
Absolute Contraindication	Patients with known hypersensitivity to Ornidazole or any other nitroimidazole derivatives.
	Patients with organic Central Nervous System (CNS) diseases (e.g., severe epilepsy or multiple sclerosis).
Conditional/Restricted Use	Patients with severe hepatic impairment (liver disease) require the dosing interval to be officially doubled to prevent drug accumulation.
	Pregnant women and nursing mothers are not recommended to use Giro, especially in the first trimester of pregnancy, unless use is deemed absolutely necessary by a physician.
	Patients with a history of blood disorders require pre- and post-treatment leukocyte (white blood cell) monitoring.

Age-Related Eligibility and Condition-Specific Rules

Use is generally established for adults and children (often with weight-based dosing criteria), but eligibility is limited or not established in infants and very young children below certain age or weight thresholds. For older adults, special caution is required due to the potential for concurrent medical issues. Patients with renal impairment typically do not require dose adjustment, but those undergoing hemodialysis require a supplemental dose.

What should I know about interactions with other medicines?

Giro Interactions with other medicines and products

Giro (Ganciclovir) has a significant potential for drug interactions, mainly involving the risk of increased toxicity or altered drug levels. It is essential to monitor for combinations that affect the bone marrow or kidney function.

Clinically Significant Interactions

The concomitant use of Giro with certain medicinal products can increase the risk of serious side effects. For example, Imipenem-cilastatin is known to increase the risk of generalized seizures when administered with Giro, and this combination is generally not recommended unless the benefits strongly outweigh the risks.

Increased Toxicity

Certain drugs that cause myelosuppression (bone marrow suppression), such as Zidovudine or other cytotoxic agents, can enhance the potential for neutropenia (low white blood cell count) and anemia when taken with Giro. Similarly, co-administration with other drugs known to be nephrotoxic (kidney-damaging), like Cyclosporine or Amphotericin B, may increase the risk of kidney damage. Frequent monitoring of blood counts and kidney function is crucial in these cases.

Altered Drug Levels

Interactions can also occur through competition for renal tubular secretion, the main elimination pathway for Giro. Probenecid is a well-documented example that can significantly increase the blood concentration of Giro, potentially raising the risk of Giro-related toxicity. Conversely, Giro may increase the plasma levels of certain co-administered drugs like Didanosine, requiring careful monitoring for increased Didanosine-related side effects.

Mechanism of Action

The action of Giro is defined by its selective cytotoxicity, engaging in a destructive cascade exclusively within susceptible pathogens. The active ingredient, Ornidazole, functions as an inert prodrug. Its mechanism is initiated within the low-oxygen (anaerobic) environment of susceptible bacteria and protozoa, where specific microbial reductase enzymes capture electrons from the pathogen's metabolic pathways. This process chemically transforms the prodrug into a highly reactive, toxic intermediate known as a nitro free radical. The formation of this radical is prevented in human (aerobic) cells, defining the drug's selectivity. Once formed, the nitro radical anions immediately attack the pathogen’s fundamental genetic material, DNA. This interaction is destructive, causing fragmentation and loss of structural integrity. This irreversible damage completely halts the organism's ability to replicate, transcribe, and repair itself. The culminating physiological consequence is the cell death of the susceptible pathogen, which is the mechanism underpinning the cessation of pathogen viability.

Dosage and Administration Information

How to Use Giro: Official Administration Guidelines

The correct use of Giro is governed by specific instructions which define the standardized procedure for administration and dosing. This information details the logistics of use, ensuring consistency in therapeutic application.

Administration Scope

Usage Rule	Official Instruction
Route of Administration	Oral (by mouth)
Standard Dosing Schedule	X mg twice daily (every 12 hours)
Duration of Therapy	Full 10-day course must be completed
Timing in relation to meals	May be taken with or without food
Preparation Requirements	None; solid oral forms must be swallowed whole
Age-Group Rules	Dosage adjustments are required for the pediatric population and are typically weight-based.

Procedural Instructions

Missed Dose Protocol:

If a dose of Giro is missed, the standardized protocol is to take the dose as soon as it is remembered. However, if it is closer to the time of the next scheduled dose (e.g., within 6 hours of the next dose), the missed dose must be skipped, and the regular twice-daily schedule should be resumed. Patients are instructed never to take two doses to make up for a single missed dose.

Special Procedural Conditions:

To maintain the integrity of the medication's intended release profile, the oral dosage form (tablet or capsule) must be swallowed whole with a full glass of water. The medicine must not be crushed, chewed, or split before ingestion, as this alters the approved method of administration.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Giro (Ornidazole)

Evidence for Amoebiasis and Giardiasis Studies

Giro (Ornidazole) was studied for its use in addressing protozoal infections like Amoebiasis and Giardiasis. Research primarily involved Randomized Controlled Trials (RCTs) and active-control studies that applied in studies examining patient-reported experiences related to discomfort. Researchers monitored study participants, including both adults and children, who received varying short-term schedules. Research explored how symptoms evolved and monitored the clearance of the protozoal organism. Comparative trials described patterns observed when Ornidazole was assessed against other agents in the nitroimidazole class. Follow-up durations were limited, typically assessing outcomes shortly after treatment, meaning there is limited information for long-term outcomes regarding the durability of the effect.

Evidence for Surgical Prophylaxis

Ornidazole was evaluated in settings designed to prevent infections that may occur after certain surgical procedures. The evidence relies on large RCTs and systematic reviews that research examined outcomes for adult patients undergoing specific procedures, focusing on the Surgical Site Infection (SSI) rate in the 30 days following the operation. Findings indicate patterns related to SSI rates when Ornidazole was used as a component of the prophylactic regimen, compared to control groups in the study. The research provides limited insight into the effect of Ornidazole was observed in isolation, as it is often studied as an adjunct to other antibiotics.

Evidence for Bacterial Vaginosis and Other Anaerobic Infections

Research was studied for its use in conditions such as Bacterial Vaginosis (BV) and localized anaerobic bacterial infections. The available research includes RCTs and systematic reviews that monitored clinical cure rates and explored outcomes related to recurrence. For BV, long-term effects are not fully established, and data are still emerging regarding recurrence rates. For other anaerobic infections, the evidence quality varies across studies, and the studies often reflect the drug’s use as an auxiliary treatment.

Research Gaps and Follow-up Limitations

The primary limitation is that follow-up durations were limited across many key trials, meaning that long-term effects are not fully established regarding recurrence and sustainability of outcomes. The evidence for certain groups, such as older adults or patients with complex comorbidities, is limited. Research provides context but not individual predictions, especially if an individual belongs to a population that was not the primary focus of the clinical trials.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Giro (FAQ)

Q: What is the maximum daily dose of Giro for an adult?

Official regulatory documents indicate that dosing for Giro is tailored to the specific infection being treated. Clinical protocols have utilized various treatment amounts for adults, depending on the prescribed regimen and the nature of the infection.

Q: Is Giro used to treat the flu or a common cold?

Official product information indicates that Giro is specifically indicated for infections caused by certain types of susceptible protozoa and anaerobic bacteria. It is not listed for use against viral illnesses, such as the common cold or flu.

Q: Can a pharmacist fill a 30-day supply, or is it only available as a 10-day treatment?

Official regulatory documents indicate that the duration of therapy may vary depending on the condition being addressed. While a full 10-day course is often specified for the standard indication, the length of treatment is determined by the specific clinical protocol being followed.

Q: Can I crush the Giro tablet to mix it in a drink?

The official label explicitly states that the oral tablet form of Giro must be swallowed whole with a full glass of water. The label notes that crushing, chewing, or splitting the medicine is not permitted, as this alters the approved method of administration.

How should Giro be stored and disposed of?

Official Storage and Disposal Requirements for Giro

The required storage and disposal instructions for Giro are strictly defined by regulatory labeling to ensure product integrity and public safety.

Storage Constraints

Giro must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The medication must be protected from excessive heat, light, and moisture, and it is explicitly stated that Giro should not be frozen. Always keep the product in its original, tightly closed container.

Stability and Protection

To prevent accidental ingestion, the medication must be kept out of the reach and sight of children. If the product requires reconstitution, refer to the labeling for specific in-use stability periods and the required storage temperature for the prepared solution.

Disposal Rules

Unused or expired Giro should be disposed of according to official guidelines. This typically involves returning the product to an authorized drug take-back location. If this is unavailable, the government-approved method for household disposal must be followed, which strictly prohibits flushing the medicine down the toilet or drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

India

Russia

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z